Veterinary Diagnostics

Meet us at the following exhibitions 2023

European Congress of Clinical Microbiology & Infectious Diseases, Copenhagen 2023, April 15-18. Read more »

Danske Dyrlægeforening Årsm. 2019, Nyborg Strand, Sep 27-28. Read more »

Veterinärkongressen 2019, Stockholm, Sep 26-28. Read more »

VeTA-dagarna, Jönköping, March 29-31. Read more »

BSA Meeting, Göteborg, Jan 19-20. Read more »

Worldwide Distributors

Worldwide Distributors

Click here to find your local distributor »
Sign up to become our distributor »



Products

TurboReader™ Point-of-Care Instrument

A compact Nephelometric diagnostic reader with barcode scanner & touch screen graphical display that performs measurements in minutes using disposable cuvettes. Easy-to-use and is compatible with serum, plasma or whole blood. Precision & accuracy comparable to routine analyzers found in central laboratories.

Specifications:
Time to Result: 3-6 min
Throughput: 15 /hr
External printer: optional
Tests: CRP, SAA, HPT, (Hb)
Size: H12 D14 W22 cm
Weight: 1 kg
Voltage: 100-240 V

Art. No. 2200-05

Equine ALB TurboReader™ Assay

An in vitro immune nephelometric assay for the quantitative determination of Albumine (ALB) in horse serum or plasma. ALB is a useful tool for assesing liver and kidney diseases. Its normal plasma concentrations in healthy horses is 26-37 g/l.

Specifications:
Species: Horse (equine)
Sample: Serum or Plasma
Sample volume: 10 μl
Range:5.0 – 75.0 g/l
Time to Result: 3 min
Kit size: 20 tests
Control: Sold separately

Art. No. 2535-01

Canine CRP TurboReader™ Assay

An in vitro immuno nephelometric assay for the quantitative determination of Canine C-Reactive (CRP) in dog serum or plasma. Canine CRP is real-time marker for systemic inflammation and infection, as well as, response to ongoing clinical treatment. Normal serum concentrations in healthy dogs is well below 35 mg/l.

Specifications:
Species: Dog (canine)
Sample: Serum or Plasma
Sample volume: 20 μl
Range: 5 – 300 mg/l
Time to Result: 3 min
Kit size: 40 tests
Control: Sold separately

Art. No. 2530-01

Equine U-ALB TurboReader™ Assay

An in vitro immune nephelometric assay for the quantitative determination of Albumine (U-ALB) in horse urine. U-ALB is a useful tool for assesing kidney function in horses. Its normal urine concentrations in healthy horses is <20-25 mg/l.

Specifications:
Species: Horse (equine)
Sample: Urine
Sample volume: 25 μl
Range:25 – 375 mg/l
Time to Result: 3 min
Kit size: 20 tests
Control: Sold separately

Art. No. 2535-02

Feline Hp TurboReader™ Assay

An in vitro immuno nephelometric assay for the quantitative determination of Haptoglobin (Hp) in cat serum or plasma. Measurement of Hp is used as a long-term monitor of inflammation or presence of subclinical disease. Low Hp indicates hemolytic anemia. Its normal concentration in healthy cats is <250 mg/dl.

Specifications:
Species: Cat (feline)
Sample: Serum or Plasma
Sample volume: 20 μl
Range:17 – 1000 mg/dl
Time to Result: 3 min
Kit size: 20 tests
Control: Sold separately

Art. No. 2532-01

EurisTest™ Turbidimetric Assay cCRP

For quantitative, in vitro determination of Canine of Canine C-Reactive (CRP) in dog plasma or serum, as a tool for monitoring systemic inflammation and managing ongoing clinical treatment. Reagent kit is used with the large clinical analyzers (Abbott Architect, Olympus etc) in central labs.



Specifications:
Species: Dog (canine)
Sample: Serum or Plasma
Sample volume: 15 μl
Range: 5 – 200 mg/l
Time to Result: 10 min
Kit size: 100 tests
Control: Sold separately

Art. No. 2510-02

Feline SAA TurboReader™ Assay

An in vitro immuno nephelometric assay for the quantitative determination of Serum Amyloid A (SAA) in cat serum or plasma. SAA is a sensitive and early acute phase protein in cats peaking around 24 hours after onset of systemic inflammation or tissue injury. Its normal plasma concentrations in healthy cats is <10 mg/l.

Specifications:
Species: Cat (feline)
Sample: Serum or Plasma
Sample volume: 10 μl
Range: 10 – 225 mg/l
Time to Result: 9.5 min
Kit size: 20 tests
Control: Sold separately

Art. No. 2533-01

Pancreas Elastase 1 Quick Canine Test

A lateral flow assay for detecting canine pancreatic elastase1 in stool samples. This test allows for the fast and reliable diagnosis or exclusion of Exocrine Pancreatic Insufficiency (EPI). A positive result indicates normal exocrine pancreatic function. A negative result indicates EPI.


Specifications:
Species: Dog (canine)
Sample: Stool
Sample volume: Use extraction tool
Result: Visual
Time to Result: 10 min
Kit size: 5 tests

Art. No. SCH-25-I

Equine SAA TurboReader™ Assay

An in vitro immune nephelometric assay for the quantitative determination of Serum Amyloid A (SAA) in horse serum or plasma. SAA is an early and sensitive inflammatory marker for detecting and monitoring disease activity and response to treatment therapy. Its normal plasma concentrations in healthy horses is <20 mg/l.

Specifications:
Species: Horse (equine)
Sample: Serum or Plasma
Sample volume: 10 μl
Range:10 – 600 mg/l
Time to Result: 9.5 min
Kit size: 20 tests
Control: Sold separately

Art. No. 2534-01

Abacus Vet5 Hematology Analyzer


Vet5 offers 5-part WBC differential results for animals. Features a touch screen and an intuitive user interface for veterinary clinics and research which require a high-quality hematology analyzer. 5-part: dog, cat, horse and cattle. 3-part: mouse, rat, rabbit, ferret, pig, sheep, goat, guinea pig & primates

Specifications:
Throughput: 25 /hr
Parameters: 22 parameter CBC w/ 5-part WBC diff & 4 cellular histograms
Technology: Impedance
Sample: 25/50 µl EDTA
Reagent: Vet5 pack (200 cycles) & blood controls

Art. No. DIT-AV5

About Us

The European Institute of Science AB is a manufacturer of diagnostic assays for the clinical laboratory and point-of-care settings, as well as, point-of-care instrumentation for diagnostic applications. Our mission is to provide veterinary and medical professionals with high-quality and accurate diagnostic tests and point-of-care instrumentation required for health care needs.

With a strong focus on veterinary health, the company’s primary focus is diagnostic assays and instrumentation for canine, feline and equine animals. In order to provide a complete veterinary product line, the European Institute of Science AB is also a distributor within Scandinavia for veterinary diagnostic products produced by external manufacturers.

The European Institute of Science AB has been a unique center of excellence within innovation and entrepreneurship for more than 25 years. Together with public financing provided by the company’s shareholders, the Institute has been able to create and develop more than ten high-tech patent families and the following four public companies: Biotech-IgG/Chemel AB (founded 1996), Genovis AB (founded 1999), Implementa Hebe AB (founded 2000) and LifeAssays AB (founded 2000). The company is situated at the IDEON research park in Lund, Sweden where it has a sales office and research facilities. Additionally, the company has production facilities near the international airport Kastrup in Denmark.

Quality Policy

The management at the European Institute of Science AB is committed to maintaining a comprehensive Quality System for the development, production and sales of safe & effective, high-quality diagnostic products. We achieve our commitment to quality by complying with all applicable regulatory requirements and by striving towards continuous improvement and high customer satisfaction.

Investors

TurboReader demonstrationsfilm den 16 mars 2018: TurboReader

Investeringsdagen Stockholm den 9 december 2019: Vd Presentation

The European Institute of Science Inc. is a public shareholding company, which has been in existence for more than 25 years. Inventor & founder,dr. Dario Kriz, started the company in Malmoe, Sweden during 1990 with the core business centered around subcontracting and resale of laboratory equipment to chemical laboratories. During the first five years, the Institute built-up a mechanical & electronic workshop and a broad international network of subcontractors. A standard of professional craftsmanship was developed which is evident in today’s prototype constructions.

During 1994 the Institute established itself in the Science park IDEON (Lund, Sweden). This transfer of the activities from the location in Malmoe showed to be a strategically very successful step. Almost instantaneously, the Institute was carried along in a wave of intensive high-tech research resulting in several unique products. Four different off-spring companies have been created around medical and biotechnical products developed within the Institute’s research facilities: Biotech-IgG AB (Chemel AB), Genovis AB, Implementa Hebe AB, and LifeAssays AB.

The Institute went public during the fall of 1998 by conducting a public share issue in Sweden. The raised capital was used to help establish the European Institute of Science as a center of excellence in medical & biotechnology seen today. The know-how which has been built-up in the company since its foundation is currently used to develope diagnostic assays for the clinical laboratory and point-of-care settings, as well as, point-of-care instrumentation for diagnostic applications.

dr. Lars-Olof Hansson

dr. Lars-Olof Hansson, born in 1944, is the Chairman since 2004. He became M.D. in 1977, specialist in clinical chemistry in 1984, Ph.D. in medicine in 1996, and associate professor in 1998. He was previously the Head of the department of Clinical chemistry and pharmacology at the Academic Hospital in Uppsala (Sweden). He has over 50 scientific publications. He holds 22 182 shares of class B in European Institute of Science AB. Personal homepage: www.linkedin.com

dr. Dario Kriz

dr. Dario Kriz, born in 1965, is a board member since 1990 and was the president from 1990 to 2022. He became Ph.D. in Biochemistry in 1994, visiting professor at the University of Regensburg (Germany) during 1997-1998, associate professor in 2004, and Honorary Consul for Republic of Slovenia to Kingdom of Sweden in 2015. He is the inventor of several products and methods in medical technology and biotechnology. He has 25 scientific publications and 13 approved patents. He has been CEO, chairman and board member of several stock listed companies. Together with his spouse, he holds 8 448 shares of class A and 3 500 shares of class B in European Institute of Science AB. Personal homepage: www.linkedin.com

dr. Kirstin Kriz

dr. Kirstin Kriz, born in 1975, is the president since 2022 and a board member since 2004. She became B.S. (University of California, San Diego, USA) in 1996, and Ph.D. in Biochemistry in 2003. Dr. Kriz has been awarded with several prestigious distinctions such as UCSD Regents Scholarship in 1995, UCSD Undergraduate Scholarship in 1996, and Phi Beta Kappa lifetime membership in 1997 for her academic achievements at the University of California San Diego, UCSD. She has 7 scientific publications. Together with her spouse, she holds 8 448 shares of class A and 3 500 shares of class B in European Institute of Science AB.

Rikard Krook

Rikard Krook, born 1967, is a board member since 2021. He holds a M.Sc. (1992) and a Degree of Licentiate of Science (1996) in Chemical Engineering, University of Lund. He has been working for Alfa Laval Lund AB since 1998 in various marketing and sales management positions with global responsibility as Global sales manager and Business Area manager for Life Science and Agri industries. Together with his spouse, he holds 233 shares of class B in European Institute of Science AB.

Since 1997, European Institute of Science has been involved in developing industrial and laboratory small molecule and IgG analysis systems for the company Biotech-IgG (previously Chemel) AB, Lund (Sweden). Our success record in this particular case involved the securing of funding in the amount of approximately 10 million USD, development of 3 different patent families (instruments and procedures), acquiring EMC certification for instruments, and finally launching the products on the laboratory market. In 2009, the company acquired a Danish diagnostic kit distribution company group and thereby gained access to a professional sales organization with a net annual sales of approximately 2 million USD. During 2011-2017, European Institute of Science AB has engaged in assisting Biotech-IgG AB to expand its business into immunodiagnostics. During 2017, European Institute of Science AB sold out its share in Biotech-IgG AB. Click here to visit the Biotech-IgG homepage.

During the period 2000 to February 2011, European Institute of Science has been involved in developing a new Point-of-Care blood analysis system for the company LifeAssays AB, Lund (Sweden). Our success record in this particular case involved the securing of funding in the amount of approximately 10 million USD, development of 7 different patent families (instrument, reagents and locked reagent data processing), acquiring EMC & ISO certification and environmental regulation permit, preparing for human IVD-CE registration (which was obtained in June 2011), and finally launching the product on the veterinary market. The product has been used to help several thousands of dog patients and reduced the unnecessary use of antibiotics for non-bacterial infections. At the end of 2010 LifeAssays had stable and growing production and sales levels, which led to the entry of the Swedish industrialist Sten K Johnsson who acquired the majority of the shares in LifeAssays. During 2011, European Institute of Science AB sold out its share in LifeAssays AB. Click here to visit the LifeAssays homepage.

Since 2000, European Institute of Science has been involved in developing laboratory magnetic stirrers with cooling and heating capabilities for the company Implementa Hebe AB, Lund (Sweden). Our success record in this particular case involved the securing of funding in the amount of approximately 0,7 million USD, development of 3 different patent families (instruments and magnetic particles), acquiring EMC certification for instruments, and finally launching the products on the laboratory market. In 2010, the company acquired a patent portfolio from European Institute of Science (magnetic field generator and magnetic peptide nanoparticles) intended for therapeutic applications. During 2006, European Institute of Science AB sold out its share in Implementa Hebe AB. Click here to visit the Implementa Hebe homepage.

During the period 1999 to 2005, European Institute of Science has been involved in developing a new gene transfer system for the company Genovis AB, Lund (Sweden). Our success record in this particular case involved the securing of funding in the amount of approximately 2 million USD, development of 3 different patent families and design of the instrument and magnetic nanoparticles. In 2006, the Swedish industrialist Bo Håkansson acquired the majority of the shares in Genovis AB. During 2007, European Institute of Science AB gradually sold out its share in Genovis AB in order to focus on new innovation challenges. Click here to visit the Genovis homepage.

European Institute of Science AB’s share has been listed on Spotlight Stock Market since February 18, 2009 under the ticker EURI B and is traded through banks and stockbrokers.

European Institute of Science AB (Org. No. 556404-2769) applies the Swedish Code of Corporate Governance ("the Code") as of February 1, 2010. The Code complements the external rules which affect the Corporate Governance, which is constituted mainly by the Companies Act, Accountancy legislation and current listing agreement. European Institute of Science applies fiscal financial year 1 Jan – 31 Dec, and will account for any deviations from the Code in a Corporate Governance report which will be attached to the Annual Report.These documents are available for downloading:

Documents

Protokoll bolagsstämmor/Minutes from General Meetings

(in Swedish)

Auditor (Revisor)

  • Mazars AB / Anders Persson, auktoriserad revisor

(In swedish only)

2023 Q1 Q2 Q3 Q4
2022 Q1 Q2 Q3 Q4 Year
2021 Q1 Q2 Q3 Q4 Year
2020 Q1 Q2 Q3 Q4 Year
2019 Q1 Q2 Q3 Q4 Year
2018 Q1 Q2 Q3 Q4 Year
2017 Q1 Q2 Q3 Q4 Year
2016 Q1 Q2 Q3 Q4 Year
2015 Q1 Q2 Q3 Q4 Year
2014 Q1 Q2 Q3 Q4 Year
2013 Q1 Q2 Q3 Q4 Year
2012 Q1 Q2 Q3 Q4 Year
2011 Q1 Q2 Q3 Q4 Year
2010 Q1 Q2 Q3 Q4 Year
2009 Q1 Q2 Q3 Q4 Year
2008 Q1 Q2 Q3 Q4 Year
2007 Q1 Q2 Q3 Q4 Year
2006 Q1 Q2 Q3 Q4 Year
2005 Q1 Q2 Q3 Q4 Year
2004 Q1 Q2 Q3 Q4 Year
2003 Q1 Q2 Q3 Q4 Year
2002 N/A N/A Q3 Q4 Year
Sign up to receive our press-releases (in swedish only) »
  • April 10, 2024 - Kommuniké extra bolagsstämma
  • March 28, 2024 - Redovisning av nettoomsättningen för första kvartalet 2024
  • March 11, 2024 - Rättelse av Kallelse till extra bolagsstämma i European Institute of Science AB
  • March 9, 2024 - Kallelse till extra bolagsstämma i European Institute of Science AB
  • March 6, 2024 - Styrelsens förslag till företrädesemission på 4.166 MSEK inför extra bolagsstämma
  • January 31, 2024 - Bokslutskommuniké 2023-01-01 till 2023-12-31
  • January 8, 2024 - Distributionsavtal för Italien tecknat med FIORAVANTI AGENCY
  • November 30, 2016 - Valberedning och Årsstämma 2017
  • November 30, 2016 - Delårsrapport 2016-01-01 till 2016-09-30
  • October 25, 2016 - EURIS senarelägger publicering av delårsrapport (Q1-3) 2016
  • August 31, 2016 - Halvårsrapport 2016-01-01 till 2016-06-30
  • August 17, 2016 - Sista dag för handel med BTA
  • Juli 5, 2016 - Utfall nyemission
  • Juni 27, 2016 - European Institute of Science får exklusiv distributionsrätt i Sverige, Danmark och Norge genom avtal med ScheBo Biotech AG
  • Juni 21, 2016 - Bolaget har erhållit sin andra order för sitt nya patientnära veterinärdiagnostiska system av nyutnämnd distributör i Litauen
  • Juni 14, 2016 - Bolaget har erhållit sin första order för sitt nya patientnära veterinärdiagnostiska system
  • Juni 7, 2016 - Publicering av Emissionsmemorandum
  • Juni 3, 2016 - Kommuniké från extra bolagsstämman 2016-06-03
  • Juni 1, 2016 - Bolagets tecknar sitt första distributionsavtal inom veterinärdiagnostik med distributör i Taiwan
  • Maj 13, 2016 - Förslag till dagordning och beslut på extra bolagsstämma 2016-06-03
  • Maj 3, 2016 - Kallelse till extra bolagsstämma den 3:e juni 2016
  • April 29, 2016 - Delårsrapport 2016-01-01 till 2016-03-31
  • Mars 22, 2016 - European Institute of Science öppnar Webbshop för global direktförsäljning av bolagets veterinära produkter
  • Mars 11, 2016 - Dagordning/förslag inför årsstämma 2016
  • Mars 4, 2016 - Bolagets instrument för veterinärdiagnostik erhåller viktig EMC CE märkning enligt EN 61326-1: 2012 och EN 61326-2-3: 2012
  • February 24, 2016 - Kallelse till årsstämma den 1:e april 2016
  • February 19, 2016 - Bolaget öppnar ett nytt laboratorium på IDEON
  • February 1, 2016 - Distributionsavtal tecknat med Primer Design Ltd
  • January 29, 2016 - Bokslutskommuniké 2015-01-01 till 2015-12-31

Contact

European Institute of Science AB
org.nr. 556404-2769

Ideongatan 1A
SE-223 70 Lund, Sweden

Tel: +46 46 286 22 30
Fax: +46 46 12 98 79

info@euris.org
www.euris.se

Distributors

Sweden Denmark Hungary Italy Lithuania Slovenia Taiwan

Sign up to become our distributor »